Novo Nordisk A/S Sponsored ADR (NVO)
The Best Could Be Yet to Come for Novo Nordisk and Ozempic
Novo Nordisk's top-two blockbuster drugs include the same active ingredient -- semaglutide. The company is testing an even higher-dose version of semaglutide, which may yield even better results.
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
Novo Nordisk (NVO) closed the most recent trading day at $142.50, moving +0.01% from the previous trading session.
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
The Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a hearing focusing on U.S. prices for weight loss drugs Ozempic and Wegovy.
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
3 Stocks to Sell as Ozempic Surges in Popularity
Novo Nordisk's (NYSE: NVO ) Ozempic diabetes treatment, marketed as a weight loss treatment under the Wegovy brand name, has become the latest mega-blockbuster drug. Yet, while you may be thinking about ways to capitalize on its popularity and the rise of other glucagon-like peptide-1 (GLP-1) weight loss treatments, you should also consider the stocks to sell because of this trend.
US Senate panel to weigh Novo Nordisk subpoena over Ozempic, Wegovy prices
The U.S. Senate health panel said on Tuesday it would vote later this month on whether to subpoena Novo Nordisk over the high U.S. prices for weight loss drugs Ozempic and Wegovy compared to those offered in other countries.
Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Here's Why Demand for Ozempic and Wegovy Could Soar Even Higher
Novo Nordisk has two hugely successful assets in Ozempic and Wegovy. A recent trial also found semaglutide effective for treating chronic kidney disease.
Novo Nordisk's Ozempic sales double to $700 M in China, driven by weight-loss demand
Last year, Novo Nordisk, the Danish pharmaceutical giant, witnessed a significant surge in the sales of its diabetes drug Ozempic in China, doubling its revenue to almost $700 million. This remarkable growth accounts for 5 percent of Ozempic's global sales, underscoring China's pivotal role in the drug's international market.
Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
Novo Nordisk is working hard to expand Ozempic's addressable market. The drug is helpful in treating chronic kidney disease, per a new trial.
European stocks open higher as markets anticipate first ECB rate cut since 2019; Novo Nordisk up 3.5%
European stocks opened higher Thursday, with markets anticipating the ECB will cut borrowing costs for the first time since September 2019.
